{"id":59540,"date":"2024-06-17T01:05:51","date_gmt":"2024-06-16T23:05:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/"},"modified":"2024-06-17T01:05:51","modified_gmt":"2024-06-16T23:05:51","slug":"mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/","title":{"rendered":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024"},"content":{"rendered":"
\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC).<\/p>\n

<\/a>
<\/a><\/p>\n

\nConference call details:<\/p>\n

\nMonday June 17, 2024<\/p>\n

\n8:30 a.m. ET \/ 5:30 a.m. PT<\/p>\n

Dial-in:<\/p>\n

\nU.S.\/Toll-Free: +1 833 470 1428<\/p>\n

\nInternational: +1 404 975 4839<\/p>\n

\nPasscode: 205511<\/p>\n

\nYou may also access the call via webcast by visiting the Events & Presentations<\/a> section on Mirum\u2019s website. A replay of this webcast will be available for 30 days.<\/p>\n

\nAbout Mirum Pharmaceuticals, Inc.<\/b><\/p>\n

\nMirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI\u00ae (maralixibat) oral solution<\/a>, CHOLBAM\u00ae (cholic acid) capsules<\/a>, and CHENODAL\u00ae (chenodiol) tablets<\/a>.<\/p>\n

\nLIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. LIVMARLI has received positive opinion by CHMP in Europe for the treatment of PFIC in patients three months of age and older. A decision by the European Commission is expected by the third quarter of 2024. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).<\/p>\n

\nMirum\u2019s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS<\/a> study for primary sclerosing cholangitis and Phase 2b VANTAGE<\/a> study for primary biliary cholangitis. Lastly, CHENODAL has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported<\/a> in 2023.<\/p>\n

\nTo learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a> and Twitter (X)<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors:
\n
Andrew McKibben
\n
ir@mirumpharma.com<\/a><\/p>\n

\nMedia:
\n
Erin Murphy
\n
media@mirumpharma.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC). Conference … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-59540","format-standard","category-industry"],"yoast_head":"\nMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC). Conference ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-16T23:05:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024\",\"datePublished\":\"2024-06-16T23:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240616032628\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/\",\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240616032628\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"datePublished\":\"2024-06-16T23:05:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240616032628\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240616032628\\\/en\\\/746217\\\/22\\\/Mirum_Inline_FullColor_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/","og_locale":"en_US","og_type":"article","og_title":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend","og_description":"FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis (PBC) and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis (PSC). Conference ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-06-16T23:05:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024","datePublished":"2024-06-16T23:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/"},"wordCount":412,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/","url":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/","name":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","datePublished":"2024-06-16T23:05:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240616032628\/en\/746217\/22\/Mirum_Inline_FullColor_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mirum-pharmaceuticals-to-host-investor-call-to-share-interim-analysis-results-from-the-volixibat-vantage-and-vistas-studies-on-june-17-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59540"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59540\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}